The 2005 genetics chapter got the timelines mostly right. It got the machines, companies, and methods mostly wrong.
Seven approved RNAi drugs, one CRISPR medicine for sickle cell, and a stem-cell cure inching toward filing — but every one arrived through mechanisms Kurzweil did not forecast in 2005.